罗氏Roche Holdings（RHHBY）2009年年度报告「OTC」.pdf

1、7 000 844ERoche|Annual Report 2009Key figures1 Key figures indexed to 2007=100.2 Before exceptional items.3 Proposed by the Board of Directors.4 Development phase I to IV.5 For calculation of the Eco-Efficiency Rate see: for 2007 as in Annual Report 2008.For a full index of Global Reporting Initiati

2、ve(GRI)indicators used in the report see: ance Report 2009F.Hoffmann-La Roche Ltd4070 Basel,Switzerland 2010 70 846 Excellence in Science09Roche Annual Report All trademarks are legally protected.00_Umschlag_ausgeschossen_ENG indd 129 01 2010 14:20:50Key figures1 Key figures indexed to 2007=100.2 Be

3、fore exceptional items.3 Proposed by the Board of Directors.4 Development phase I to IV.5 For calculation of the Eco-Efficiency Rate see: for 2007 as in Annual Report 2008.For a full index of Global Reporting Initiative(GRI)indicators used in the report see: figures indd 129 01 2010 14:20:10The year

4、 2009 in brief GroupGroup sales increase by 10%1 to 49.1 billion Swiss francs(8%in Swiss francs;7%in US dollars).Both divisions gain market share.Operating profit before exceptional items increases by 14%(8%in Swiss francs)to 15.0 billion Swiss francs due to strong sales growth and continuing produc

5、tivity improvements;at the same time investments in research and development increase by 12%to 9.9 billion Swiss francs.Effective 26 March 2009,Roche obtains full ownership of Genentech for a price of 47.0 billion US dollars,or 52.7 billion Swiss francs.Genentech integration has been completed.Net i

6、ncome of 8.5 billion Swiss francs,down by 22%compared with the previous year due to exceptional items relating to the Genentech transaction and integration.Excluding exceptional items,the Genentech transaction is already contributing to income:income attributable to Roche shareholders increases by 9